Volume | 4,508 |
|
|||||
News | - | ||||||
Day High | 3.40 | Low High |
|||||
Day Low | 3.35 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aspira Womans Health Inc | AWH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.35 | 3.35 | 3.40 | 3.40 | 3.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
80 | 4,508 | $ 3.38 | $ 15,219 | - | 2.3087 - 6.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:43:26 | 1 | $ 3.15 | USD |
Aspira Womans Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
41.35M | 10.34M | - | 9.15M | -16.69M | -1.61 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aspira Womans Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AWH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.50 | 3.57 | 3.2501 | 3.48 | 8,345 | -0.10 | -2.86% |
1 Month | 3.50 | 3.675 | 2.51 | 3.05 | 25,944 | -0.10 | -2.86% |
3 Months | 5.43 | 5.615 | 2.51 | 3.78 | 23,966 | -2.03 | -37.38% |
6 Months | 5.28 | 5.65 | 2.49 | 3.87 | 36,929 | -1.88 | -35.61% |
1 Year | 5.418 | 6.75 | 2.3087 | 4.15 | 67,011 | -2.02 | -37.25% |
3 Years | 90.75 | 95.85 | 2.3087 | 25.94 | 431,320 | -87.35 | -96.25% |
5 Years | 62.10 | 158.10 | 2.3087 | 44.00 | 506,571 | -58.70 | -94.52% |
Aspira Womans Health Description
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. |